BRPI0614122B8 - composto derivado de quinolina, composição farmacêutica e uso do referido composto - Google Patents
composto derivado de quinolina, composição farmacêutica e uso do referido compostoInfo
- Publication number
- BRPI0614122B8 BRPI0614122B8 BRPI0614122A BRPI0614122A BRPI0614122B8 BR PI0614122 B8 BRPI0614122 B8 BR PI0614122B8 BR PI0614122 A BRPI0614122 A BR PI0614122A BR PI0614122 A BRPI0614122 A BR PI0614122A BR PI0614122 B8 BRPI0614122 B8 BR PI0614122B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compound
- pharmaceutical composition
- quinoline
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000186367 Mycobacterium avium Species 0.000 abstract 1
- 241000186366 Mycobacterium bovis Species 0.000 abstract 1
- 241000187492 Mycobacterium marinum Species 0.000 abstract 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- -1 QUINOLINE DERIVATIVE COMPOUND Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05106962.3 | 2005-07-28 | ||
| EP05106962 | 2005-07-28 | ||
| PCT/EP2006/064656 WO2007014885A1 (en) | 2005-07-28 | 2006-07-26 | Antibacterial quinoline derivatives |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0614122A2 BRPI0614122A2 (pt) | 2011-03-09 |
| BRPI0614122A8 BRPI0614122A8 (pt) | 2019-01-29 |
| BRPI0614122B1 BRPI0614122B1 (pt) | 2020-09-24 |
| BRPI0614122B8 true BRPI0614122B8 (pt) | 2023-01-10 |
Family
ID=35610159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0614122A BRPI0614122B8 (pt) | 2005-07-28 | 2006-07-26 | composto derivado de quinolina, composição farmacêutica e uso do referido composto |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7915292B2 (enExample) |
| EP (1) | EP1912948B1 (enExample) |
| JP (1) | JP5100647B2 (enExample) |
| KR (1) | KR101334719B1 (enExample) |
| CN (1) | CN101273016B (enExample) |
| AP (1) | AP2322A (enExample) |
| AR (1) | AR054587A1 (enExample) |
| AU (1) | AU2006274918B2 (enExample) |
| BR (1) | BRPI0614122B8 (enExample) |
| CA (1) | CA2614981C (enExample) |
| CY (1) | CY1117247T1 (enExample) |
| DK (1) | DK1912948T3 (enExample) |
| EA (1) | EA015617B1 (enExample) |
| ES (1) | ES2554924T3 (enExample) |
| HR (1) | HRP20151308T1 (enExample) |
| HU (1) | HUE026259T2 (enExample) |
| IL (1) | IL188987A0 (enExample) |
| JO (1) | JO3077B1 (enExample) |
| MX (1) | MX2008001219A (enExample) |
| MY (1) | MY148219A (enExample) |
| NO (1) | NO341795B1 (enExample) |
| NZ (1) | NZ565946A (enExample) |
| PL (1) | PL1912948T3 (enExample) |
| PT (1) | PT1912948E (enExample) |
| RS (1) | RS54382B1 (enExample) |
| SI (1) | SI1912948T1 (enExample) |
| TW (1) | TWI427065B (enExample) |
| UA (1) | UA94051C2 (enExample) |
| WO (1) | WO2007014885A1 (enExample) |
| ZA (1) | ZA200800783B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080076924A1 (en) * | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
| WO2011144444A1 (en) * | 2010-05-21 | 2011-11-24 | Syngenta Participations Ag | Novel amides as fungicides |
| AU2013254670B2 (en) | 2012-04-27 | 2017-03-30 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| ES2576491T3 (es) | 2012-04-27 | 2016-07-07 | Janssen Pharmaceutica, N.V. | Derivados de quinolina antibacterianos |
| ES2596243T3 (es) * | 2012-08-24 | 2017-01-05 | F. Hoffmann-La Roche Ag | Nuevos derivados bicíclicos de piridina |
| CN104650054B (zh) * | 2013-11-25 | 2019-09-13 | 重庆医药工业研究院有限责任公司 | 一种抗结核菌的喹啉噻吩芳氧乙胺衍生物 |
| CN105175329B (zh) * | 2014-06-10 | 2017-09-19 | 重庆圣华曦药业股份有限公司 | 一种贝达喹啉消旋体的合成路线及方法 |
| US20190321324A1 (en) * | 2016-12-30 | 2019-10-24 | Board Of Regents, The University Of Texas System | Quaternary amine antibiotic therapeutics |
| CN110804016B (zh) * | 2019-12-05 | 2022-11-04 | 福建省微生物研究所 | 抗结核分枝杆菌的二芳基喹啉衍生物 |
| US20240287022A1 (en) * | 2021-06-28 | 2024-08-29 | Merck Sharp & Dohme Llc | Il4i1 inhibitors and methods of use |
| CN117843568A (zh) * | 2024-01-03 | 2024-04-09 | 中国药科大学 | 一种芳烷基取代-1-甲基喹啉季铵盐类衍生物及其制备方法和用途 |
| CN119666810A (zh) * | 2025-02-19 | 2025-03-21 | 吉林国际旅行卫生保健中心(长春海关口岸门诊部) | 基于图像处理的舌拭子样本荧光检测结核分歧杆菌的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1041035A3 (ru) * | 1982-02-25 | 1983-09-07 | Киорин Сейяку Кабусики Кайся (Фирма) | Способ получени производных хинолинкарбоновой кислоты,их гидратов или солей |
| JPS6463518A (en) * | 1987-09-02 | 1989-03-09 | Otsuka Pharma Co Ltd | Antiarrhythmic agent |
| US5235054A (en) * | 1992-07-15 | 1993-08-10 | Pfizer Inc. | 3-carboxaldehyde substituted quinolines and naphthyridines |
| DE69518075T2 (de) * | 1994-05-24 | 2001-03-22 | F. Hoffmann-La Roche Ag, Basel | Tricyclische dicarbonylderivate |
| CN1307565A (zh) * | 1998-04-29 | 2001-08-08 | 史密丝克莱恩比彻姆有限公司 | 用作mrs抑制剂和杀菌剂的喹诺酮化合物 |
| SI1527050T1 (sl) | 2002-07-25 | 2010-08-31 | Janssen Pharmaceutica Nv | Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji |
-
2006
- 2006-07-11 JO JOP/2006/0218A patent/JO3077B1/ar active
- 2006-07-26 WO PCT/EP2006/064656 patent/WO2007014885A1/en not_active Ceased
- 2006-07-26 MY MYPI20063590A patent/MY148219A/en unknown
- 2006-07-26 HU HUE06777972A patent/HUE026259T2/en unknown
- 2006-07-26 HR HRP20151308TT patent/HRP20151308T1/hr unknown
- 2006-07-26 BR BRPI0614122A patent/BRPI0614122B8/pt not_active IP Right Cessation
- 2006-07-26 DK DK06777972.8T patent/DK1912948T3/en active
- 2006-07-26 SI SI200631998T patent/SI1912948T1/sl unknown
- 2006-07-26 US US11/996,786 patent/US7915292B2/en active Active
- 2006-07-26 UA UAA200800826A patent/UA94051C2/ru unknown
- 2006-07-26 CA CA2614981A patent/CA2614981C/en not_active Expired - Lifetime
- 2006-07-26 NZ NZ565946A patent/NZ565946A/en not_active IP Right Cessation
- 2006-07-26 EA EA200800455A patent/EA015617B1/ru unknown
- 2006-07-26 ES ES06777972.8T patent/ES2554924T3/es not_active Expired - Lifetime
- 2006-07-26 JP JP2008523352A patent/JP5100647B2/ja not_active Expired - Fee Related
- 2006-07-26 MX MX2008001219A patent/MX2008001219A/es active IP Right Grant
- 2006-07-26 KR KR1020087004457A patent/KR101334719B1/ko not_active Expired - Fee Related
- 2006-07-26 CN CN200680035175XA patent/CN101273016B/zh not_active Expired - Fee Related
- 2006-07-26 RS RS20150796A patent/RS54382B1/sr unknown
- 2006-07-26 PL PL06777972T patent/PL1912948T3/pl unknown
- 2006-07-26 AU AU2006274918A patent/AU2006274918B2/en not_active Ceased
- 2006-07-26 AP AP2008004308A patent/AP2322A/xx active
- 2006-07-26 EP EP06777972.8A patent/EP1912948B1/en not_active Expired - Lifetime
- 2006-07-26 PT PT67779728T patent/PT1912948E/pt unknown
- 2006-07-27 TW TW095127409A patent/TWI427065B/zh not_active IP Right Cessation
- 2006-07-27 AR ARP060103260A patent/AR054587A1/es unknown
-
2008
- 2008-01-24 IL IL188987A patent/IL188987A0/en active IP Right Grant
- 2008-01-25 ZA ZA200800783A patent/ZA200800783B/xx unknown
- 2008-02-27 NO NO20081008A patent/NO341795B1/no not_active IP Right Cessation
-
2015
- 2015-12-08 CY CY20151101113T patent/CY1117247T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0720220B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
| EA200602260A1 (ru) | Применение замещенных хинолиновых производных для лечения заболеваний, вызываемых микобактериями, резистентными к лекарственным средствам | |
| BRPI0312927B8 (pt) | "compostos, derivados de quinolina, composição, seu uso como inibidores micobacteriais, bem como processo para preparação dos referidos derivados". | |
| CY1117247T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
| BR112022000782A2 (pt) | Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica | |
| CL2009001267A1 (es) | Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis. | |
| ZA202203107B (en) | Azaindole carboxamide compounds for the treatment of mycobacterial infections | |
| MX2014013056A (es) | Derivados de quinolina antibacterianos. | |
| CY1112230T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| BRPI0719939B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
| BRPI0720251B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo | |
| CY1112027T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| MX2014013055A (es) | Derivados de quinolina antibacterianos. | |
| BRPI0612534B8 (pt) | uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto | |
| BRPI0806997A2 (pt) | Derivado de 4-amino-quinolia, composição farmacêutica, e, uso de um derivado de 4-amino-quinolina ou um sal de adição farmaceuticamente aceitável do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/07/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2594 DE 24/09/2020 QUANTO AO INVENTOR POR ERRO MATERIAL DO TITULAR. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2785 DE 21-05-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |